Corvus Pharmaceuticals (CRVS) Fair Value & DCF
Score
CRVS fair value $3.77. Price $10.64. Price is 182% above fair value.
Worked example
No cash-flow value. Free cash flow is not steady enough to discount.
Earnings value. Next-twelve-months earnings per share of $0.13 times 28.43 is $3.77. The peer group is Biotechnology, 13 companies worth at least $10 billion. This stock has no 10-year median P/E, so the peer median of 28.4 is kept between 8 and 30, which is 28.43.
Fair value is the earnings value, $3.77. The price is $10.64, which is 182.4% above fair value.